Search PubMed⌕ Search

Biomedical subjects

G Mumtaz

Publications and source records attributed to G Mumtaz.

27 records · Page 2Linked to original sources
PubMed1984

The activity of ciprofloxacin and other 4-quinolones against Chlamydia trachomatis and Mycoplasmas in vitro.

Ciprofloxacin was found to be the most active of a group of 4-quinolone antibiotics tested against the SA2f strain of Chlamydia trachomatis (MBC and MIC 1.0 mg/l). Against genital isolates of Chlamydia trachomatis, ciprofloxacin was twice as active as rosoxacin. Ciprofloxacin showed similar activity to that of oxytetracycline against clinical isolates of Mycoplasma hominis and Ureaplasma urealyticum, and was 8-fold more active than rosoxacin against the latter.

4-Quinolones↗
PubMed1983

The activity of miokamycin (MOM) against Chlamydia trachomatis and mycoplasmas in vitro.

The activity of miokamycin, a new macrolide, was investigated against Chlamydia trachomatis, Ureaplasma urealyticum and Mycoplasma hominis, in vitro. Miokamycin was found to be similar in activity to doxycycline and erythromycin against Chlam. trachomatis and U. urealyticum. Against Mycopl. hominis, miokamycin had an activity clearly superior to erythromycin.

Anti-Bacterial Agents↗
PubMed1982

Provision of a chlamydial culture service to a sexually transmitted diseases clinic.

Urethral specimens from 215 men were inoculated on to McCoy cell cultures, both at the local laboratory and at a central reference laboratory, Chlamydia trachomatis was isolated from 58 (28%) patients; 12 of these isolates were, however, obtained only at the local laboratory. The results show the feasibility and convenience of a central laboratory supplying a peripheral laboratory with uninoculated prepared cell cultures. Such a service is not only more cost effective but obviates the problems of transporting specimens to a central laboratory.

Bacteriological Techniques↗
PubMedDate not supplied

Comparative in vitro activity of lomefloxacin, a difluoro-quinolone.

Lomefloxacin is a new difluoro-quinolone. In this study, we have determined the in vitro activity of lomefloxacin against a wide range of clinical bacterial isolates and compared it with that of other fluoro-quinolones and some unrelated antimicrobials. Lomefloxacin was very active against Enterobacteriaceae (MIC90, 0.5 micrograms/ml) with activity comparable to that of ofloxacin (MIC90, 0.25 micrograms/ml). Lomefloxacin was moderately active against isolates of Pseudomonas aeruginosa (MIC90, 4 micrograms/ml), and again the activity was comparable to ofloxacin (MIC90, 4 micrograms/ml) but was eightfold less than ciprofloxacin (MIC90, 0.5 micrograms/ml). Lomefloxacin was also active against isolates of Staphylococcus aureus (MIC90, 1 micrograms/ml), irrespective of methicillin susceptibility, and this activity was most comparable to ofloxacin (MIC90, 0.5 micrograms/ml) and ciprofloxacin (MIC90, 0.5 micrograms/ml). Lomefloxacin was fourfold less active than either ofloxacin or ciprofloxacin against isolates of Enterococcus faecalis (MIC90, 8 micrograms/ml) and Streptococcus pneumoniae (MIC90, 8 micrograms/ml). In common with ofloxacin and ciprofloxacin, lomefloxacin was very active against isolates of Neisseria spp. (MIC90, less than or equal to 0.06 micrograms/ml), Haemophilus spp. (MIC90, less than or equal to 0.06 micrograms/ml), Legionella spp. (MIC90, less than or equal to 0.06 micrograms/ml), Vibrio spp. (MIC90, less than or equal to 0.06 micrograms/ml), and Campylobacter jejuni (MIC90, 1 microgram/ml). Lomefloxacin showed poor activity against isolates of Bacteroides spp. (MIC90, 16 micrograms/ml) or Clostridium difficile MIC90, 32 micrograms/ml) and was only moderately active against isolates of Clostridium perfringens (MIC90, 2 micrograms/ml), Peptostreptococcus spp. (MIC90, 4 micrograms/ml), Chlamydia trachomatis (MIC90, 4 micrograms/ml), Mycoplasma hominis (MIC90, 2 micrograms/ml), and Urea-plasma urealyticum (MIC90, 8 micrograms/ml). Lomefloxacin was found to be bactericidal at concentrations generally close to the MIC with greater than 3 log10 reduction in viability of exponentially dividing cultures of Escherichia coli and S. aureus within 5 hr of exposure to concentrations at eight times the MIC. These results indicate a potential clinical role for lomefloxacin in the treatment of genitourinary tract infections caused by Gram-positive and Gram-negative bacteria, respiratory tract infections caused by susceptible organisms, and soft tissue infections caused by S. aureus.

4-Quinolones↗
PubMedDate not supplied

Activity of thiamphenicol against Chlamydia trachomatis and Neisseria gonorrhoeae.

The in-vitro activity of thiamphenicol against Neisseria gonorrhoeae was compared with that of penicillin. A total of 267 isolates were tested. All strains were inhibited by less than or equal to 4.0 micrograms of thiamphenicol/ml. However, the minimal inhibitory concentration of thiamphenicol was fourfold higher (MIC90 = 2.0 micrograms/ml) for beta-lactamase-producing strains or those moderately resistant to penicillin than for penicillin-sensitive strains (MIC90 = 0.5 micrograms/ml). The MIC of thiamphenicol for Chlamydia trachomatis was determined for a control strain and for 15 recent clinical isolates. The MIC90 for thiamphenicol was 1.0 micrograms/ml, as compared with a MIC90 of oxytetracycline of 0.12 micrograms/ml against the same isolates.

Chlamydia trachomatis↗
PubMedDate not supplied

Azithromycin vs doxycycline in the treatment of non-gonococcal urethritis.

Azithromycin is a novel azalide macrolide active against Chlamydia trachomatis and Ureaplasma urealyticum. High persistent tissue concentrations allow short courses or even single doses to be considered. Sixty-two patients were studied, 19 received azithromycin 1 g in a single dose, 22 received azithromycin 500 mg in a single dose on day 1 followed by 250 mg once daily for 2 days and 21 received doxycycline 200 mg in a loading dose followed by 100 mg every 12 h for 7 days. Efficacy of these 3 regimens was compared in the treatment of non-gonococcal urethritis (NGU). Clearance of C. trachomatis from post-treatment cultures was satisfactory with all regimens. Response defined as the absence of symptoms and reduction in polymorphonuclear leucocytes in a Gram stained smear of urethral secretion to less than 5 cells per hpf (x 100 objective) was statistically better for the 3 day regimen of azithromycin than for the other 2 regimens. All treatments were well tolerated. Three days or single doses of azithromycin compared to 7 days of tetracycline (or 10-14 days as is often prescribed) have obvious advantages for patient compliance.

Administration, Oral↗
PubMedDate not supplied

Evaluation of an enzyme immunoassay (Chlamydiazyme) with confirmatory test for the detection of chlamydial antigen in urine from men.

First catch urine specimens from 312 male patients were examined for the presence of chlamydial antigen by an enzyme immunoassay (Chlamydiazyme). Positive results were repeated and confirmed using a blocking assay. In addition, urethral swabs were examined by cell culture for Chlamydia trachomatis. Discrepant results were further analysed by direct immunofluorescence (IF) of the spun urine deposit. Paired specimens were positive from 26 subjects, and negative from 276 subjects. Eight paired specimens were urethral culture positive, and urine EIA negative. Two specimens, urine EIA positive but urethral culture negative, were positive on direct IF. The sensitivity, specificity, predictive value of a positive result, and predictive value of a negative result for urine EIA against cell culture and/or direct IF were 77.8%, 100%, 100% and 97.2% respectively.

Chlamydia Infections↗